Hikma Ventures invests in Propeller Health for the enhancement of leading respiratory technology platform

London, 20 October 2016 – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its venture capital arm, Hikma International Ventures and Development LLC (Hikma Ventures) has participated in a $21.5 million series C round of financing for Propeller Health.

Press Release Corporate 20 October 2016

Propeller Health has developed a digital platform that integrates information from multiple sources and uses
machine intelligence to recommend an optimal path therapy for individuals who suffer from chronic obstructive
pulmonary disease (COPD), asthma and other respiratory diseases. This technology provides a novel combination
of sensors, mobile applications, data analytics and personalised feedback, encouraging patient adherence to
maintenance therapy. The Propeller Health device and technology has been used by patients with respiratory
diseases in over 40 commercial programmes across the U.S., including major healthcare systems, payers and
employers. The Propeller Health device is compatible with the majority of commonly used asthma and COPD inhaler
devices including controller and reliever metered dose inhalers, and other inhaler devices (dry powder inhaler and
soft mist inhaler). Propeller has partnered with several companies including Vectura Group to develop an add-on
sensor for Vectura’s lever-operated multi-dose inhaler.
Hikma Ventures’ investment will be supporting the expansion of Propeller Health’s digitally guided therapy
platform and modernise the management of respiratory disease. The market size for digital dose inhalers for
asthma and COPD is expected to reach around $3.6 billion in 20241
Lana Ghanem, Managing Director of Hikma Ventures, said, “Our investment in Propeller Health demonstrates our
focus on identifying and investing in innovative, high potential digital health providers. We are very excited to be
supporting the development of Propeller’s technology platform, which is enabling physicians, patients and providers
to have advanced access to better quality data as well as improved medication adherence in the growing respiratory
David Van Sickle, CEO of Propeller Health, said, “Despite an abundance of effective treatments, the majority of
people with chronic respiratory disease could be doing much better than they are. We’re excited to work with
Hikma Ventures on our efforts to develop information-powered medicines that help people and their physicians
achieve control of these conditions.”

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.